Lastly, given the heterogeneity among entities (molecular subgroups, aggressiveness, tissue), this ratio could help predicting the B cell lymphoma patients who would benefit to BCL2 specific BH3-mimetic based therapy. The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.